Fighting Cancer Together
Simplifying Development and Manufacturing of Personalized Therapies
This article is posted on Sartorius Blog.
Cancer remains a leading cause of death worldwide. Sartorius helps to simplify the development and manufacturing of personalized cancer therapies.
Cancer remains a leading cause of death worldwide. The International Agency for Research on Cancer estimates that in 2022 there were 20 million new cases and 9.7 million cancer‑related deaths. Projections suggest that by 2050 new cases could rise by more than 70%. The disease’s complexity, with countless types and subtypes, makes universal diagnostic and treatment approaches impossible.
At the same time, medical progress is enabling increasingly personalized and targeted therapies. Sartorius supports these advances with bioprocessing technologies and analytical tools that help accelerate the development and production of new cancer treatments.
Advancing CAR-T Cell Therapies
Significant progress in treating various forms of blood cancer has been achieved with CAR-T cell therapies. However, producing these individualized treatments remains complex, time‑consuming, and costly. Sartorius T Cell Manufacturing Solutions help address the challenges by automating production steps and integrating quality‑control tools, supporting the cost‑effective production of high‑quality CAR‑T therapies.
Teams are also working with customers to develop a fully automated, end-to-end platform for CAR-T cell manufacturing. This platform aims to simplify the entire journey from cell extraction to reinfusion, improving efficiency and supporting better outcomes for patients and healthcare providers.
In 2025, Sartorius entered into a partnership with Nanotein Technologies, a developer of next-generation immune cell activation reagents. These reagents are designed to enhance the expansion and quantity of T cells and natural killer (NK) cells - two key immune cell types used in various cell therapy applications.
A Reliable Partner for Cancer Treatments
Other advanced cancer treatments include monoclonal antibodies and mRNA vaccines, which help the immune system target cancer cells in different ways.
Sartorius supports these approaches with solutions across the entire research and production workflow: from bioanalytical instruments that accelerate therapy development to Ambr® and Biostat STR® bioreactors for scalable manufacturing, as well as specialized media, reagents, data analytics, and purification and filtration technologies.
Racing Against Cancer Together
In addition to advancing the development and manufacturing of cancer treatments, Sartorius teams regularly support social initiatives in the fight against cancer.
Last year, colleagues in Aubagne, France, participated in "Pink October", a month dedicated to raising awareness about breast cancer screening. The team set up an information and prevention booth, which was very well received by employees. Also turning pink, the team in Yauco, Puerto Rico, helped raise breast cancer awareness by organizing the "Running for Her" event. In addition, colleagues joined the "Run or Walk for Them" run and hosted a talk on cervical cancer awareness. The Havant team in UK supported two initiatives: "Movember", complete with bold mustaches, fundraising, and some brave waxing, and "Wear a Hat", where colourful headgear and generous donations helped raise awareness of brain tumours. In Göttingen, Germany, more than 100 colleagues joined a stem cell donor registration drive, adding valuable new chances for patients with leukemia to find a matching donor.
Find out more on the official website
